Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02051764 · ClinicalTrials.gov registry record · Phase 2
Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
A Phase 2 study, sponsored by Avid Radiopharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT02051764 is a Phase 2 study that was terminated before completion, run by Avid Radiopharmaceuticals. The registered enrollment target is 44 participants.
The verdict
NCT02051764, a Phase 2 study, was terminated before completion, sponsored by Avid Radiopharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study will evaluate the imaging characteristics of flortaucipir in subjects with a previous flortaucipir scan in order to assess the rate of change of tau deposition over time.
Interventions
- DRUG Flortaucipir F18
- PROCEDURE Brain PET Scan
- DRUG Florbetapir F 18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02051764
The ClinicalTrials.gov registry entry for NCT02051764 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Flortaucipir F18 is the first listed.
NCT02051764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02051764 about?
NCT02051764 is a clinical study titled "Imaging Characteristics of a Follow-up 18F-AV-1451 Scan". This study will evaluate the imaging characteristics of flortaucipir in subjects with a previous flortaucipir scan in order to assess the rate of change of tau deposition over time.
What is the current status of trial NCT02051764?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2014-05. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02051764?
The interventions under investigation include: Flortaucipir F18 (DRUG), Brain PET Scan (PROCEDURE), Florbetapir F 18 (DRUG).
Who is sponsoring clinical trial NCT02051764?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.